跳到正文
原文
Nature 健康护理主题·· 2026-10-06AI 评分49

骨髓纤维化患者接受αβTCR与CD19去除干细胞移植时围移植期使用ruxolitinib的研究

Peri-transplant ruxolitinib in myelofibrosis patients undergoing αβTCR and CD19-depleted stem cell transplantation

AI 导读

荷兰乌得勒支大学医学中心团队在Bone Marrow Transplantation发表研究,聚焦骨髓纤维化患者在接受αβTCR与CD19去除异基因造血干细胞移植期间使用ruxolitinib。

正文

Data availability

The data that support the findings of this study are available from the EBMT registry, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are, however, available from the authors upon reasonable request and with permission of the corresponding author.

References

  1. McLornan D, Eikema DJ, Czerw T, Kroger N, Koster L, Reinhardt HC, et al. Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis. Bone Marrow Transpl. 2021;56:2160–72.

    Article  CAS  Google Scholar 

  2. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787–98.

    Article  CAS  PubMed  Google Scholar 

  3. Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382:1800–10.

    Article  PubMed  Google Scholar 

  4. Kroger N, Shahnaz Syed Abd Kadir S, Zabelina T, Badbaran A, Christopeit M, Ayuk F, et al. Peritransplantation ruxolitinib prevents acute graft-versus-host disease in patients with myelofibrosis undergoing allogenic stem cell transplantation. Biol Blood Marrow Transpl. 2018;24:2152–6.

    Article  Google Scholar 

  5. Hobbs GS, Haesook TK, Hao R, Schroeder MA, Tamari R, Wall S, et al. Phase II study of peri- and post-transplant ruxolitinib for patients with myelofibrosis receiving allogeneic hematopoietic cell transplantation. JCO Oncol Adv. 2025;2:1–10.

    Google Scholar 

  6. Stuut AHG, Nijssen C, van der Wagen L, van Rhenen A, Daenen LGM, Janssen A, et al. Improved GVHD-free and relapse-free survival after ex vivo αβTCR and CD19 depleted allogeneic HSCT compared to T cell replete HSCT. Bone Marrow Transplant. 2025;60:673–81.

  7. Kunte S, Rybicki L, Viswabandya A, Tamari R, Bashey A, Keyzner A, et al. Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. Leukemia. 2022;36:856–64.

    Article  CAS  PubMed  Google Scholar 

  8. Chiusolo P, Bacigalupo A, Salit R, Schroeder T, Finazzi MC, Gurnari C, et al. PTCy or ATG for Matched Transplantation in Myelofibrosis. Am J Hematol. 2026;101:1192–5.

  9. Oechsler S, Gagelmann N, Wolschke C, Janson D, Badbaran A, Klyuchnikov E, et al. Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2024;59:550–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Salit RB, Hexner EO, Gagelmann N, Kroger N, McLornan DP, Jain T, et al. Defining remission following hematopoietic cell transplant for myelofibrosis: an international expert panel consensus. Leukemia. 2025;39:2862–5.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Gagelmann N, Wolschke C, Badbaran A, Janson D, Berger C, Klyuchnikov E, et al. Donor lymphocyte infusion and molecular monitoring for relapsed myelofibrosis after hematopoietic cell transplantation. Hemasphere. 2023;7:e921.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Gagelmann N, Quarder M, Badbaran A, Rathje K, Janson D, Luck C, et al. Clearance of driver mutations after transplantation for myelofibrosis. N Engl J Med. 2025;392:150–60.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

Dutch Cancer Society (KWF; #13493) to MdW, Leukemiefonds to MdW.

Author information

Author notes

  1. These authors contributed equally: Anniek Stuut, Flores Weverling.

  2. These authors jointly supervised this work: Jurgen Kuball, Moniek de Witte.

Authors and Affiliations

  1. Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands

    Anniek Stuut, Flores Weverling, Julia Drylewicz, Jurgen Kuball & Moniek de Witte

  2. Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands

    Flores Weverling, Anke Janssen, Frances Verheij, Iris Brinkman, Klaartje Nijssen, Pleun Schonewille, Christien Oudbier, Anna van Rhenen, Lotte van der Wagen, Laura Daenen, Reinier Raymakers, Jurgen Kuball & Moniek de Witte

  3. Cell Therapy Facility, University Medical Center Utrecht, Utrecht, The Netherlands

    Kasper Westinga

  4. Central Diagnostic Laboratory, University Medical Center Utrecht, Utrecht, The Netherlands

    Tim Hutten & Lisette van de Corput

Authors

  1. Anniek Stuut
  2. Flores Weverling
  3. Anke Janssen
  4. Frances Verheij
  5. Iris Brinkman
  6. Klaartje Nijssen
  7. Pleun Schonewille
  8. Christien Oudbier
  9. Anna van Rhenen
  10. Lotte van der Wagen
  11. Laura Daenen
  12. Reinier Raymakers
  13. Kasper Westinga
  14. Tim Hutten
  15. Lisette van de Corput
  16. Julia Drylewicz
  17. Jurgen Kuball
  18. Moniek de Witte

Contributions

MdW was responsible for the conception and design of the study. MdW and JK were responsible for funding acquisition. AS, FW, JD, JK, and MdW contributed to data analysis and interpretation. AS, FW, JK, and MdW were responsible for writing the manuscript and preparing the figures. AS and FW had full access to and verified the underlying data. AJ, CO, AvR, LvdW, LD, RR, JK, and MdW were responsible for resource provision (patients). AS, FW, and MdW were responsible for manuscript submission. AS, FW, FV, IB, KN, PS, KW, TH, and LvdC were responsible for the collection and assembly of data. All authors critically revised the manuscript and approved the final version.

Corresponding author

Correspondence to Moniek de Witte.

Ethics declarations

Competing interests

JK is inventor on multiple patents dealing with gdTCRs, ligands, isolation strategies of engineered immune cells. JK is cofounder and shareholder of Gadeta (www.gadeta.nl). JK received research, advisor and clinical study support from Miltenyi Biotech. JK received further research support from Novartis and Gadeta.

Consent for publication

All eligible patients provided written informed consent before transplantation. The study was approved by the Medisch Ethische Toetsingscommissie Utrecht (METC Utrecht, METC nr 21-322), in accordance with the Declaration of Helsinki.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stuut, A., Weverling, F., Janssen, A. et al. Peri-transplant ruxolitinib in myelofibrosis patients undergoing αβTCR and CD19-depleted stem cell transplantation. Bone Marrow Transplant (2026). https://doi.org/10.1038/s41409-026-03063-0

Download citation

  • Received: 05 June 2026

  • Revised: 07 September 2026

  • Accepted: 21 September 2026

  • Published: 06 October 2026

  • Version of record: 06 October 2026

  • DOI: https://doi.org/10.1038/s41409-026-03063-0

来源:Nature 健康护理主题 · nature.com